Kitaura, Takashi, Naoko Tsunekawa, and Hideo Hatta. Decreased monocarboxylate transporter 1 in rat soleus and EDL muscles exposed to clenbuterol. J Appl Physiol 91: [85][86][87][88][89][90] 2001.-We hypothesized that a shift in muscle fiber type induced by clenbuterol would change monocarboxylate transporter 1 (MCT1) content and activity of lactate dehydrogenase (LDH) and isoform pattern and shift myosin heavy chain (MHC) pattern in soleus (Sol) and extensor digitorum longus (EDL) of male rats. In the clenbuteroladministered rats (2.0 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 subcutaneously for 4 wk), the ratio of muscle weight to body weight increased in the Sol (P Ͻ 0.05) and the EDL (P Ͻ 0.01). Clenbuterol induced the appearance of fast MHC 2D and decreased slow MHC1 in Sol (13%) but had no effect on EDL. The MHC pattern of Sol changed from slow to fast type. Clenbuterol increased LDH-specific activity (P Ͻ 0.01) and the ratio of the muscle-type isozyme of LDH to the heart type (P Ͻ 0.05) in Sol. The LDH total activity of the EDL muscle was also increased (P Ͻ 0.05). Furthermore, MCT1 content significantly (P Ͻ 0.05) decreased in both Sol and EDL (27 and 52%, respectively). This study suggests that clenbuterol might mediate the shift of MHC from slow to fast type and the changes in the regulation of lactate metabolism. Novel to this study is the observation that clenbuterol decreases MCT1 content in the hindlimb muscles and that the decrease in MCT1 is not muscle-type specific. It may suggest that the genetic expressions of individual factors involving slow-type MHC, heart-type isozyme of LDH, and MCT1 are associated with one another but are regulated independently. lactate dehydrogenase; myosin heavy chain; ␤ 2-agonist; transition CLENBUTEROL IS ONE OF THE selective ␤ 2 -adrenergic-receptor agonists and is mainly used as a bronchodilator and tocolytic agent to relax the uterus. It also has potent anabolic properties (2, 9, 14, 35); thus its usage as a drug for doping is banned by many athletic committees (33). However, there are still unclear effects on lipid metabolism, thermogenesis, and hyperglycemia (25, 43). The higher distribution of ␤ 2 -receptors in slow-twitch muscle (i.e., the increased intracellular cAMP via the receptor) is one of the plausible explanations of the specific effect of clenbuterol on the slowtype muscles, including the transition of myosin types from slow to fast and the metabolic shift from oxidative to anaerobic glycolysis (22, 39). Lactate dehydrogenase (LDH) plays a pivotal role in anaerobic glycolysis (11). The ratio between the muscle-type isozyme (LDH-M), which has a higher K m to pyruvate, and the heart type (LDH-H), which has a lower K m to pyruvate, is an important index of the glycogen and lactate metabolism of skeletal muscle (37). Increased lactate or LDH-M activity in the soleus (Sol) muscle was reported, and the increase in glycolysis was suggested to be due to the administration of clenbuterol (26, 40). Lactate not only is an end product of glycolysis and glycogenolysis but is also a substrate for oxidation and gluconeogenesis (6, 18, 19) . Several recent studies have shown that movement of lactate across the sarcolemma depends, in part, on a monocarboxylate transporter (MCT) (6, 8, 17, 18, 31) . It has been reported that there are eight isoforms of MCT (5, 20, 23, 34) . MCT1 is present in rats mainly in oxidative red muscles and in the heart (1, 31). Recently, showed that MCT1 was located in the sarcolemmal membrane as well as the mitochondria. They showed that MCT4 was also located in the sarcolemmal membrane (15). In cell-cell interaction, the uptake of lactate in red muscles and in the heart is increased when MCT1 increases after endurance training. Therefore, MCT1 is highly related to the oxidative capacities of skeletal muscles and their capacity to take up lactate extracellularly (3, 4, 17, 33) and intracellularly (7, 8) . It has been suggested that the higher distribution of LDH-H subunits is related to MCT1 distribution in skeletal muscles (27, 28) . In slow-twitch muscles, the shift of metabolic property from oxidative to glycolytic with clenbuterol is demonstrated by increased phosphofructokinase activity and decreased citrate synthase activity (14), as well as decreased ratio of LDH-H to LDH-M (40). However, a change in MCT1 has not been reported. In the present study, we hypothesized that these shifts of metabolic and contractile properties by clenbuterol are muscle-type specific. Furthermore, we hypothesized a decrease in MCT1 in the slow-twitch muscle type, based on the evidence that ␤ 2 -receptor density has been shown to be correlated with the oxi-
lactate dehydrogenase; myosin heavy chain; ␤ 2-agonist; transition CLENBUTEROL IS ONE OF THE selective ␤ 2 -adrenergic-receptor agonists and is mainly used as a bronchodilator and tocolytic agent to relax the uterus. It also has potent anabolic properties (2, 9, 14, 35) ; thus its usage as a drug for doping is banned by many athletic committees (33) . However, there are still unclear effects on lipid metabolism, thermogenesis, and hyperglycemia (25, 43) . The higher distribution of ␤ 2 -receptors in slow-twitch muscle (i.e., the increased intracellular cAMP via the receptor) is one of the plausible explanations of the specific effect of clenbuterol on the slowtype muscles, including the transition of myosin types from slow to fast and the metabolic shift from oxidative to anaerobic glycolysis (22, 39) . Lactate dehydrogenase (LDH) plays a pivotal role in anaerobic glycolysis (11) . The ratio between the muscle-type isozyme (LDH-M), which has a higher K m to pyruvate, and the heart type (LDH-H), which has a lower K m to pyruvate, is an important index of the glycogen and lactate metabolism of skeletal muscle (37) . Increased lactate or LDH-M activity in the soleus (Sol) muscle was reported, and the increase in glycolysis was suggested to be due to the administration of clenbuterol (26, 40) . Lactate not only is an end product of glycolysis and glycogenolysis but is also a substrate for oxidation and gluconeogenesis (6, 18, 19) . Several recent studies have shown that movement of lactate across the sarcolemma depends, in part, on a monocarboxylate transporter (MCT) (6, 8, 17, 18, 31) . It has been reported that there are eight isoforms of MCT (5, 20, 23, 34) . MCT1 is present in rats mainly in oxidative red muscles and in the heart (1, 31) . Recently, Brooks et al. (6) (7) (8) showed that MCT1 was located in the sarcolemmal membrane as well as the mitochondria. They showed that MCT4 was also located in the sarcolemmal membrane (15) . In cell-cell interaction, the uptake of lactate in red muscles and in the heart is increased when MCT1 increases after endurance training. Therefore, MCT1 is highly related to the oxidative capacities of skeletal muscles and their capacity to take up lactate extracellularly (3, 4, 17, 33) and intracellularly (7, 8) . It has been suggested that the higher distribution of LDH-H subunits is related to MCT1 distribution in skeletal muscles (27, 28) . In slow-twitch muscles, the shift of metabolic property from oxidative to glycolytic with clenbuterol is demonstrated by increased phosphofructokinase activity and decreased citrate synthase activity (14) , as well as decreased ratio of LDH-H to LDH-M (40) . However, a change in MCT1 has not been reported. In the present study, we hypothesized that these shifts of metabolic and contractile properties by clenbuterol are muscle-type specific. Furthermore, we hypothesized a decrease in MCT1 in the slow-twitch muscle type, based on the evidence that ␤ 2 -receptor density has been shown to be correlated with the oxi-dative potential, the percentage of slow-type fibers (22) , and the coexpression of MCT1 and LDH-H (28) . Therefore, we evaluated clenbuterol's effects on the relationship between the metabolic changes and the shift of myosin types.
METHODS
Animal care and experimental protocols. Twelve male Sprague-Dawley rats (8 wk old) were fed rat chow and water ad libitum and were maintained on a 12:12-h light-dark photoperiod. Animal care and use protocols were in accordance with the Guiding Principles for the Care and Use of Animals approved by the Council of the Physiological Society of Japan. Two animals were housed per cage (25 ϫ 40 ϫ 20 cm), and, at 9 wk of age, animal pairs were randomly assigned to a saline (Con, n ϭ 6) or clenbuterol (Cleb, n ϭ 6) group. Clenbuterol (2 mg ⅐ kg body wt Ϫ1 ⅐ day Ϫ1 ; Sigma Chemical) was administered subcutaneously once daily for 4 wk. Con rats were injected with 0.5 ml/kg body wt of normal saline once daily for 4 wk.
Tissue sampling. At the end of the 4 wk of treatment, the animals were killed with an intraperitoneal injection of 50 mg/kg pentobarbital sodium and decapitated. The Sol and extensor digitorum longus (EDL) muscles were quickly removed and weighed. Muscle samples from the left hindlimb were used to determine LDH activity and LDH isozymes, and samples from the right hindlimb were immediately frozen in isopentane cooled by liquid nitrogen for the analysis of myosin heavy chain (MHC) isoforms and MCT1 and then stored at Ϫ80°C until the assay. Protein concentration was determined by using the bicinchoninic acid protein assay kit (Pierce, Rockford, IL) for subsequent analyses.
LDH analysis. For the analysis of metabolic property, the tissues were homogenized for 10 s in a 1:50 (wt/vol) dilution of LDH extraction buffer containing 50 mM Tris ⅐ HCl, 0.3 M sucrose, 0.1 M KCl, 1 mM EDTA, 5 mM MgCl 2, and 0.5 mM phenylmethylsulfonyl fluoride at pH 7.4 with a polytron homogenizer. Homogenates were then centrifuged at 4°C for 5 min at 600 g. The resulting supernatant produced an enzyme sample that was decanted and assayed for LDH activity and LDH isozymes (13, 42) . The LDH activity was measured spectrophotometrically by using a Monotest LDH kit from Boehringer (Mannheim, Germany). The reaction mixture was composed of 50 mM phosphate buffer (pH 7.5), 0.6 mM sodium pyruvate, and 0.18 mM NADH. After preincubation at 30°C for ϳ10 min, an enzyme sample was added to the reaction mixture, and the reaction was carried out at 30°C, measuring the average decrease in absorbance of NADH at 365 nm. The extinction coefficient of 9,118 was used to convert the absorbance change to the molar concentration of the product formed, and the values obtained were converted to those of 25°C using conversion factor 0.75. One unit of enzyme activity was defined as 1 mmol of NADH reduced per minute at 25°C.
Aliquots of the enzyme sample were also used for LDH isozyme analysis electrophoretically by using the method of Diets and Lubrano (13) . The gels were composed of 6.5% acrylamide, 0.17% N,NЈ-methylene-bis-acrylamide (bisacrylamide), 375 mM Tris ⅐ HCl (pH 8.9), 0.05% ammonium persulfate (APS), and 0.05% N,N,NЈ,NЈ-tetramethylenediamine (TEMED) and were 45 ϫ85 ϫ1 mm. Each lane was loaded with ϳ5 g of protein, and the gels were run in a vertical-slab gel system (TS-35, Wakamori, Tokyo, Japan) at 20 mA/gel (constant current) in a cold room at 4°C for 60 min. After electrophoresis, the gels were stained enzymatically in a solution containing 0.1 M sodium lactate, 10 mM NaCl, 0.5 mM MgCl 2, 1 mg/ml NAD, 0.25 mg/ml nitro blue tetrazolium, 0.025 mg/ml phenazine methosulfate, and sodium phosphate buffer, pH 7.4.
MHC analysis. MHC composition was assessed by using SDS-PAGE procedures essentially as described by Talmadge and Roy (38) . Crude myofibrillar extracts containing MHCs were obtained from samples of ϳ100 mg, pulverized in liquid nitrogen, treated with the denaturing solution (10% glycerol, 2% SDS, 5% 2-mercaptoethanol, 62.5 mM Tris ⅐ HCl, pH 6.8) for SDS-PAGE in a glass homogenizer, and heated for 5 min in boiling water.
The stacking gel consisted of 4% acrylamide, 0.08% bisacrylamide, 30% glycerol, 70 mM Tris ⅐ HCl (pH 6.8), 4 mM EDTA, 0.4% SDS, 0.1% APS, and 0.05% TEMED. The separating gel was composed of 8% acrylamide, 0.16% bis-acrylamide, 30% glycerol, 0.4% SDS, 200 mM Tris ⅐ HCl, 100 mM glycine, 0.1% APS, and 0.05% TEMED (pH 8.7). The running buffer in the upper chamber contained 100 mM Tris ⅐ HCl, 150 mM glycine, and 0.1% SDS (pH 8.3). The running buffer in the lower chamber contained 50 mM Tris ⅐ HCl, 0.075 M glycine, and 0.05% SDS. Each lane was loaded with ϳ500 ng/lane of protein, and the gels (106 ϫ 100 ϫ 1 mm) were run in an electrophoretic chamber (KS-8012, Marysol, Tokyo, Japan) at 70 V (constant voltage) in a cold room at 4°C for 22 h. After electrophoresis, the individual MHC isoforms were measured after they were shown using a silver-stain technique (30) . The MHC isoforms were identified based on data reported in the literature (36) and on digitized densitometric data sets with the use of these procedures (order of migration: fast-type 2A, fast-type 2D, fast-type 2B, and slowtype 1 MHC isoforms). The LDH isozymes or MHC isoforms were photographed, scanned with a digital imaging system, and quantified using computerized densitometry (NIH Image 1.61 analysis software).
MCT1 analysis. Polyclonal antibody directed against COOH terminus of MCT1 (NЈ-CPQQNSSGDPAEEESPV-CЈ) (23) was produced by immunizing New Zealand White rabbits with a synthetic peptide corresponding to amino acids 478-494 of MCT1 (Sawady Technology, Tokyo, Japan). This antibody was raised and affinity purified as described elsewhere (32) . The polyclonal antibody yielded a single band on a Western blot that corresponded to a molecular weight of ϳ43,000, consistent with the molecular weight reported for MCT1 (1, 17) . It was confirmed that the antibody crossreacted with MCT1 from rat and Chinese hamster, but not human, in a preliminary experiment. Sample preparation for Western blotting was done according to McCullagh et al. (28) . Briefly, muscles were homogenized in 210 mM sucrose, 2 mM EGTA, 40 mM NaCl, 30 mM HEPES, 5 mM EDTA, and 2 mM phenylmethylsulfonyl fluoride, pH 7.4. After homogenization, 1.17 M KCl and 58.3 mM tetrasodium pyrophosphate were added. After ultracentrifugation at 230,000 g for 75 min at 4°C, the supernatant fluid was discarded, and the pellet was washed and resuspended in 10 mM Tris ⅐ HCl and 1 mM EDTA, pH 7.4, solution. Then 16% of SDS solution was added. Samples were centrifuged at 1,100 g, and the supernatant was used for protein assay and Western blotting detection of MCTs. Western blotting of MCT1 was done according to McCullagh et al. (27) and Wilson et al. (41) . Samples were applied to 12% SDS-polyacrylamide gels. Proteins were transferred from the gel to membrane (Hybond-C extra, Amersham). Membranes were blocked by 20 mM Tris ⅐ HCl, 137 mM NaCl, 0.1% Tween 20, and 10% nonfat dry milk, pH 7.5, solution. Membranes were then incubated with antibody solution for 1 h. After being washed in 20 mM Tris ⅐ HCl, 137 mM NaCl, and 0.1% Tween 20, pH 7.5, membranes were incubated with donkey anti-rabbit IgG horse-86 DECREASED MCT1 IN RAT MUSCLES EXPOSED TO CLENBUTEROL radish peroxidase-conjugated secondary antibody (1:3,000; Bio-Rad) in 20 mM Tris ⅐ HCl, 137 mM NaCl, and 0.1% Tween 20, pH 7.5. MCT1 was detected using an enhanced chemiluminescence detection method (Amersham) by exposing the membrane to film (Fuji, Tokyo, Japan). Band densities of MCT1 were obtained by scanning the film and using the NIH Image 1.61 analysis software.
Statistical analyses. Differences between groups were determined using one-way ANOVA. Post hoc differences were determined with Scheffé's test and unpaired t-test where appropriate. Significance was evaluated in all statistics at P Ͻ 0.05 and/or P Ͻ 0.01. Data are reported as means Ϯ SD.
RESULTS
The effect of clenbuterol treatment on body weight and muscle wet weight of rats is shown in Table 1 . The Cleb group showed significantly lower body weight than the Con group (P Ͻ 0.05). The muscle wet weights of the Cleb group were higher than those of the Con group (P Ͼ 0.05; Table 1) in the Sol (9%) and EDL (12%), and the ratio of muscle wet weight to body weight was significantly higher (Sol: P Ͻ 0.05; EDL: P Ͻ 0.01) in the Cleb group than in the Con group. Therefore, the skeletal muscles tended to be hypertrophied as a result of clenbuterol treatment.
The MHC isoform distribution is shown in Table 2 . In the Sol, which consisted of only MHC 1 and MHC 2A , the percentage of MHC 1 decreased (P Ͻ 0.01) with clenbuterol. Furthermore, MHC 2A did not change, but MHC 2D increased (P Ͻ 0.01) in the Sol. This suggests that the transition of MHCs from slow to fast might have occurred within the muscle.
In the EDL, the percentage of fast-type MHC 2B and MHC 2D tended to increase, and both MHC 1 and MHC 2A decreased, but these differences were not significant.
The LDH activity is shown in Table 3 . Both the LDH-specific activity of Sol (P Ͻ 0.01) and the total activity were higher in Cleb rats than in Con (P Ͻ 0.05). In EDL, the total activity was significantly higher than in Con (P Ͻ 0.05).
The LDH isozyme distribution is summarized in Table 4 . In Sol, the distribution pattern of LDH isozymes shifted from LDH-H predominant to LDH-M predominant, and the ratio of LDH-M to LDH-H increased significantly with clenbuterol, but the isozymes of EDL were not affected. Figure 1 shows the MCT1 contents in Sol and EDL. MCT1 contents of the Cleb group were significantly lower (P Ͻ 0.05) than those of the Con group in both the Sol and the EDL muscles (Sol Cont vs. Cleb: 17.80 Ϯ 3.91 vs. 12.98 Ϯ 3.23%; EDL Cont vs. Cleb: 8.12 Ϯ 3.47 vs. 3.92 Ϯ 1.93% of rat heart standard). This means that clenbuterol induced the reduction of MCT1 expression in both Sol (27%) and EDL (52%).
DISCUSSION
The present study tested the hypothesis that the ␤ 2 -agonist clenbuterol would produce muscle-type-specific differential results (i.e., a slow-to-fast shift in the MHC content in the slow-twitch Sol muscle, an oxida- Values are means Ϯ SD in percent; n, no. of observations. H, heart type; M, muscle type. * Significantly different from control group, P Ͻ 0.01.
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tive-to-glycolytic metabolic shift in the LDH isoforms and the MCT1 content, but no changes in fast-twitch EDL muscle). A novel and significant finding is the demonstration that clenbuterol administration decreases MCT1 content in both Sol and EDL muscles and the decrease of MCT1 is not muscle-type specific (Fig. 1) . Our data (Tables 2-4) clearly support our hypothesis in the Sol muscle but argues against it in the fast-twitch EDL muscle. These data suggest that the genetic expressions of individual factors involving slow-type MHC, LDH-H, and MCT1 are associated with one another but are regulated independently.
Previous studies show that clenbuterol administration induces a transition from slow to fast MHC phenotypes in the slow-twitch Sol muscle (10, 14) but no change in MHCs in fast-twitch plantaris and gastrocnemius muscles (14) . In Sol muscle, our results (Table  2 ) support these findings, and the magnitude of the decrease in MHC 1 (Ϫ13%) was a little larger than that of the decrease (about Ϫ8%) in MHC 1 obtained in a prior study by Dodd et al. (14) . This difference might be due to the longer treatment of clenbuterol for 4 wk in the present study than their treatment for 2 wk. In fast-twitch EDL muscle, we also showed that there was no change in MHCs. The present study (Table 2) shows that the expression of fast-type MHCs is induced in the rat Sol by clenbuterol treatment. The MHC isoform profile shows a partial transformation toward a "fast" phenotype with a marked increase in MHC 2D and a corresponding relative decrease in slow-type MHC 1 ( Table 2 ). This shift and the enlargement of muscle (Table 1 ) may account for the increased contraction velocity and tension development in these muscles reported by others (14) . They were explained by the relationship of clenbuterol to MyoD, which regulates fast MHC synthesis, or myogenin to slow MHC (12, 29) .
MCT1 has a close relationship to lactate metabolism, and there is a significant relationship between MCT1 content and the percent muscle fiber type (slow oxidative ϩ fast oxidative glycolytic) (3, 4, 27, 28) . Therefore, as our data (Tables 2-4) show, there must be some influence on lactate metabolism and MCT1 content when the percentage of muscle-fiber-type changes (28, 31) . Although this interactive relationship between the metabolic changes and muscle-fiber composition is not established, it might be explained in part by a genetic regulation via cAMP. In our study, the relationship between the expression of MCT1 and the genetic regulation by cAMP was not tested; however, a strong inverse relationship can be expected. McCullagh et al. (27) showed that MCT1 content is inversely correlated with LDH total activity. The ␤ 2 -agonist clenbuterol increases an intracellular cAMP, which regulates the expression of cAMP response element (CRE) and CRE binding protein in the nucleus. This CRE or CRE binding protein regulates LDH-M expression (16, 24) . These data suggest that the increased cAMP stimulated by clenbuterol directly induced an increase in LDH-M in skeletal muscles (i.e., the increased LDH activity and the decreased ratio of LDH-H to LDH-M). Our data (Tables 3 and 4) in Sol muscle support this notion. The smaller distribution of the ␤ 2 -receptor in fast-twitch muscle (22) may explain the effect of clenbuterol on LDH in EDL but may not explain the significant decrease of MCT1 in EDL. Although the tendency of increased LDH-specific activity in EDL was not significant (P ϭ 0.08), the increased LDH total activity may be explained by the increased muscle mass (Table 1) . Therefore, the different response to clenbuterol in LDH and MCT1 remains to be explained. One plausible explanation is that the turnover rate of MCT1 might be faster than that of LDH. On the other hand, the genetic regulation in MCT1 expression might be different from LDH-H or LDH-M. As it is unknown whether MCT1 expression is inhibited by cAMP, the transcriptional effect of clenbuterol on MCT1 expression awaits further characterization.
MCT1 plays a role in the muscle's capacity to exchange lactate among cells, as well as to take up and oxidize lactate in cells with high mitochondrial density (15) . Slow-twitch muscles have more MCT1 in sarcolemmal and mitochondrial membranes than do fasttwitch muscles (7, 15) and may be able to oxidize more lactate than can fast-twitch muscle due to the higher LDH-H percent. As Brooks et al. (7, 8, 15) showed, the important localization of MCT1 in mitochondrial membranes and the presence of LDH-M in mitochondria should also be studied to explain the difference between Sol muscle and EDL in metabolic adaptation. The speculation that EDL has a higher distribution of LDH-M in the mitochondria-like liver may explain the lesser effects of clenbuterol on LDH and MCT1 in EDL than in Sol, which is speculated to have higher distribution of LDH-H in the mitochondria. Future investigations need to examine MCT4 as a possible candidate for intra-and extracellular lactate shuttles mechanism in the muscle (7, 15, 23 ). Furthermore, we should Fig. 1 . Monocarboxylate transporter 1 (MCT1) protein content in soleus (Sol) and extensor digitorum longus (EDL). Data were obtained from control (Cont; n ϭ 6) and clenbuterol (Cleb; n ϭ 5) groups. MCT1 in muscles is expressed as a percentage of rat heart MCT1 content, which was set to 100% for each Western blot. Values are means Ϯ SD. * Significant difference between Cont and Cleb, P Ͻ 0.05.
consider the effect of lypolysis, which is increased by clenbuterol (43) . The MCT1 in the mitochondria can transport pyruvate along with ketone bodies, resulting in the conversion to acetyl-CoA (20) . Increased acetylCoA inhibits pyruvate dehydrogenase activity in the mitochondria by end-product inhibition. This would be followed by an increase in the production of lactate due to the pyruvate dehydrogenase inhibition (21) . This sustained specific condition produced by clenbuterol may induce the downregulation of MCT1 and the upregulation of LDH-M. Thus the higher distribution of MCT1 in the mitochondria may be able to explain the faster increase of LDH-M in the Sol compared with the EDL (Tables 3 and 4) .
In conclusion, the present study shows that clenbuterol increases Sol and EDL muscle mass-to-body weight ratio, induces the appearance of the fast-type MHC 2D isoforms, and decreases the slow-type MHC 1 in Sol muscle. Finally, because clenbuterol depressed MCT1 expression in both Sol and EDL muscles, it appears that changes in MCT1 are not muscle-type specific like LDH isozymes or MHC isoforms. The present study is the first to demonstrate that clenbuterol administration decreases MCT1 concentrations in EDL as well as in Sol skeletal muscles.
